

PTO/SB/D8A (10-01)



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/656,055
Filing Date	September 5, 2003
First Named Inventor	Yaver et al.
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	10322.200-US

Sheet	2	of	2
-------	---	----	---

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published	T ²
		MORROW, Brian J. and SHAW, Karen Joy, "DNA Microarray Expression Analysis in Antibacterial Drug Discovery", Pathogen Genomics: Impact on Human Health, pp. 97-112, Humana Press Inc., Totowa, New Jersey, 2002	
		WILSON et al., "Exploring drug-induced alterations in gene expression in <i>Mycobacterium tuberculosis</i> by microarray hybridization", PNAS, October 26, 1999, Vol. 96, No. 22, p. 12833-12838	

Examiner Signature		Date Considered	2/06
-----------------------	--	--------------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.